Share Price | Edgewise Therapeutics, Inc. Stock Analysis & Recommendation

Q: How big is Edgewise Therapeutics, Inc.?

Market Cap: As of Jun 18, Edgewise Therapeutics, Inc. has a market capitalization of 1,524.35 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Edgewise Therapeutics, Inc. reported net sales of 0.00 million and a net profit of -146.09 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 459.22 million and total assets of 486.82 million.

Q: What does Edgewise Therapeutics, Inc. do?

Overview:Edgewise Therapeutics, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.Financial Snapshot:- Most recent Net Profit: -41 Million (Quarterly Results - Mar 2025)- Market cap: USD 1,524.35 Million (Micro Cap)Key Metrics:- P/E: NA (Loss Making)- Industry P/E: NA- Dividend Yield: 0.00%- Debt Equity: -1.01- Return on Equity: -34.00%- Price to Book: 3.55Contact Details:No Company Details Available.

Q: Is Edgewise Therapeutics, Inc. technically bullish or bearish?

As of 31 October 2025, the technical trend for Edgewise Therapeutics, Inc. has changed from mildly bearish to sideways. The current stance is neutral, with mixed signals across various indicators. The weekly MACD is mildly bullish, while the monthly MACD is mildly bearish. The Bollinger Bands show a mildly bullish trend on the weekly chart but bearish on the monthly. Daily moving averages indicate a mildly bearish position. The KST is bullish weekly but mildly bearish monthly, and there are no discernible trends in Dow Theory or OBV.In terms of performance, the stock has outperformed the S&P 500 over the past week and month, returning 8.08% and 10.7% respectively, while the S&P 500 returned 0.71% and 1.92%. However, year-to-date and one-year returns are significantly negative at -35.11% and -49.04%, compared to the S&P 500's positive returns of 16.30% and 19.89%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

713.36 k

Shareholding (Dec 2025)

FII

17.51%

Held by 101 FIIs

DII

26.01%

Held by 37 DIIs

Promoter

33.32%

How big is Edgewise Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Edgewise Therapeutics, Inc. has a market capitalization of $1.524 billion, with net sales of $0.00 million and a net profit of -$146.09 million over the last four quarters. The company reported shareholder's funds of $459.22 million and total assets of $486.82 million as of Dec 24.

View full answer

What does Edgewise Therapeutics, Inc. do?

22-Jun-2025

Edgewise Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $41 million and a market cap of $1.52 billion. The company has no dividend yield and negative return on equity.

View full answer

Is Edgewise Therapeutics, Inc. technically bullish or bearish?

05-Nov-2025

As of October 31, 2025, Edgewise Therapeutics, Inc. shows a neutral trend with mixed signals across indicators, having outperformed the S&P 500 recently but significantly underperformed year-to-date and over the past year.

View full answer

Compare Edgewise Therapeutics, Inc. with Similar Stocks

Scholar Rock Holding Corp.Aerovate Therapeutics, Inc.Nautilus Biotechnology, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 3,195 Million (Small Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.01

Return on Equity

-28.15%

Price to Book

5.72

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

-50 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

37.04%

6 Months

97.48%

1 Year

26.22%

2 Years

83.38%

3 Years

339.53%

4 Years

202.85%

5 Years

0.0%

Edgewise Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-230.78%

EBIT to Interest (avg)

-106.79

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.01

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

5.72

EV to EBIT

-14.55

EV to EBITDA

-14.73

EV to Capital Employed

-714.30

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-28.15%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Bullish

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Dow Theory

Mildly Bullish

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 49 Schemes (23.17%)

Foreign Institutions

Held by 101 Foreign Institutions (17.51%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is -26.45% vs -31.89% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-55.40",
          "val2": "-44.90",
          "chgp": "-23.39%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-50.20",
          "val2": "-39.70",
          "chgp": "-26.45%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -25.41% vs -33.53% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-189.10",
          "val2": "-156.50",
          "chgp": "-20.83%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-167.80",
          "val2": "-133.80",
          "chgp": "-25.41%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-55.40

-44.90

-23.39%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-50.20

-39.70

-26.45%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is -26.45% vs -31.89% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-189.10

-156.50

-20.83%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-167.80

-133.80

-25.41%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -25.41% vs -33.53% in Dec 2024

All Annual Results

Company CV

About Edgewise Therapeutics, Inc.

Edgewise Therapeutics, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available